Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune… Read more
Raphael Pharmaceutical Inc. (RAPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.013x
Based on the latest financial reports, Raphael Pharmaceutical Inc. (RAPH) has a cash flow conversion efficiency ratio of 0.013x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.00K) by net assets ($-1.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Raphael Pharmaceutical Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Raphael Pharmaceutical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Raphael Pharmaceutical Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Raphael Pharmaceutical Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SKILLCAST GROUP LS -001
F:K9I
|
N/A |
|
Electric Metals (USA) Limited
OTCQB:EMUSF
|
-0.028x |
|
Australian Unity Office Fund
AU:AOF
|
-0.011x |
|
KSB SE & Co. KGaA vz. (Pref Shares)
HM:KSB3
|
N/A |
|
Mazhar Zorlu Holding AS
IS:MZHLD
|
1.149x |
|
Green Bridge Metals Corporation
F:J48
|
0.013x |
|
Katana Capital Ltd
AU:KAT
|
-0.013x |
|
EP Manufacturing Bhd
KLSE:7773
|
0.090x |
Annual Cash Flow Conversion Efficiency for Raphael Pharmaceutical Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Raphael Pharmaceutical Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-742.00K | $-532.00K | 0.717x | +106.38% |
| 2023-12-31 | $107.00K | $-1.20 Million | -11.243x | -57.02% |
| 2022-12-31 | $106.00K | $-759.00K | -7.160x | +35.41% |
| 2021-12-31 | $128.00K | $-1.42 Million | -11.086x | -161.19% |
| 2020-12-31 | $-43.00K | $-779.00K | 18.116x | -- |